WordNet

a substance that exerts some force or effect
a businessman who buys or sells for another in exchange for a commission (同)factor, broker
any agent or representative of a federal agency or bureau (同)federal agent
a representative who acts on behalf of other persons or organizations
an active and efficient cause; capable of producing a certain effect; "their research uncovered new disease agents"
how long something has existed; "it was replaced because of its age"
a time of life (usually defined in years) at which some particular qualification or power arises; "she was now of school age"; "tall for his eld" (同)eld
begin to seem older; get older; "The death of his wife caused him to age fast"
make older; "The death of his child aged him tremendously"
antidiabetic consisting of any of several drugs that reduce the level of glucose in the blood; used to treat diabetes mellitus
of or relating to hypoglycemia; "hypoglycemic agents" (同)hypoglycaemic

PrepTutorEJDIC

『代理人』;周旋人 / 働き(作用)を起こすもの;作用物,薬剤 / (政府機関,特にFBI,CIAなどの)部員,機関員
〈U〉(一般に)『年齢』,寿命;〈C〉(個々の)『年齢』,年 / 〈U〉成年(おとなとしての資格・権利を得る年齢;通例18または21歳) / 〈U〉『老齢』;《集合的に》老人たち / 〈U〉(人生の)『一時期』;〈C〉世代(generation) / 〈U〉〈C〉《しばしばA-》(歴史上の)『時代』 / 〈C〉《話》長い間 / 年をとる,ふける;〈物が〉古くなる / 〈年〉'を'とらせる;〈物〉'を'古びさせる

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

Higher Risk of Sulfonylurea-associated Hypoglycemic Symptoms in Women with Type 2 Diabetes Mellitus.

Kajiwara A1, Kita A, Saruwatari J, Oniki K, Morita K, Yamamura M, Murase M, Koda H, Hirota S, Ishizuka T, Nakagawa K.
Clinical drug investigation.Clin Drug Investig.2015 Sep;35(9):593-600. doi: 10.1007/s40261-015-0314-6.
BACKGROUND: Although some evidence suggests that women may be at greater risk for hypoglycemia, no conclusion has been reached, and female sex has not been taken into account in antidiabetic drug-induced hypoglycemia. This study aimed to determine whether females are at a higher risk of sulfonylurea
PMID 26293520

Effects of three injectable antidiabetic agents on glycaemic control, weight change and drop-out in type 2 diabetes suboptimally controlled with metformin and/or a sulfonylurea: A network meta-analysis.

Zhong X1, Zhang T1, Liu Y2, Wei X2, Zhang X1, Qin Y1, Jin Z1, Chen Q1, Ma X1, Wang R1, He J3.
Diabetes research and clinical practice.Diabetes Res Clin Pract.2015 Sep;109(3):451-60. doi: 10.1016/j.diabres.2015.05.048. Epub 2015 Jun 5.
AIMS: The objective of this review was to assess glucagon-like peptide-1 receptor agonists (GLP-1 RAs), basal insulin, and premixed insulin among participants with type 2 diabetes inadequately controlled with metformin and/or a sulfonylurea.METHODS: We searched PubMed, EmBase, and the Cochrane Libra
PMID 26233934

Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes.

Ito D1, Iuchi T2, Kurihara S2, Inoue I2, Katayama S2, Inukai K3.
Journal of clinical medicine research.J Clin Med Res.2015 Sep;7(9):694-9. doi: 10.14740/jocmr2237w. Epub 2015 Jul 24.
BACKGROUND: Liraglutide was first released in Japan as a long-acting once-daily glucagon-like peptide-1 receptor agonist. The maximum dose in Japan is 0.9 mg/day, which is half of that used in the United States and the European Union (1.8 mg/day). The efficacy of this maximum allowable dose of lirag
PMID 26251684